ESMO Events 2024

Meetings opens in new tab/window | ESMO opens in new tab/window

Welcome to our ESMO Virtual Congress site where we showcase the very best from ESMO's flagship portfolio.

ESMO Molecular Analysis for Precision Oncology Congress 2024 opens in new tab/window

MAP focuses on current and emerging approaches in precision oncology, highlights successes and challenges, and proposes potential solutions in clinical research and practice.

This event constitutes an excellent occasion to reunite basic scientists, people working on new technologies, medical doctors, and healthcare providers.

Our globally recognised experts in the field await you for three days of discussions on discoveries in precision medicine, technologies for cancer profiling, mechanisms driving tumour expansion, metastatic dissemination, clonal evolution, and biomarker-driven development of targeted therapeutics.

Below a collection of papers recently published in ESMO’s premier journals carefully selected to reflect the themes of the meeting.

Annals of Oncology

• Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group opens in new tab/window M.F. Mosele ∙ C.B. Westphalen ∙ A. Stenzinger ∙ F. Barlesi ∙ A. Bayle ∙ I. Bièche ∙ J. Bonastre ∙ E. Castro ∙ R. Dienstmann ∙ A. Krämer ∙ A.M. Czarnecka ∙ F. Meric-Bernstam ∙ S. Michiels ∙ R. Miller ∙ N. Normanno∙ J. Reis-Filho,† ∙ J. Remon ∙ M. Robson ∙ E. Rouleau ∙ A. Scarpa ∙ C. Serrano ∙ J. Mateo ∙ F. André

• Unraveling the potential clinical utility of circulating tumor DNA detection in colorectal cancer—evaluation in a nationwide Danish cohort opens in new tab/window T.V. Henriksen ∙ C. Demuth ∙ A. Frydendahl ∙ J. Nors ∙ M. Nesic ∙ M.H. Rasmussen ∙ T. Reinert O.H. Larsen ∙ C. Jaensch ∙ U.S. Løve ∙ P.V. Andersen ∙ T. Kolbro ∙ O. Thorlacius-Ussing ∙ A. Monti ∙M. Gögenur ∙ J. Kildsig∙ P. Bondeven ∙ N.H. Schlesinger ∙ L.H. Iversen ∙ K.A. Gotschalck ∙ C.L. Andersen

• ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe opens in new tab/window A. Bayle ∙ J. Bonastre ∙ D. Chaltiel ∙ N. Latino ∙ E. Rouleau ∙ S. Peters ∙ M. Galotti ∙ G. Bricalli ∙ B. Besse,† ∙ R. Giuliani

ESMO Open

• A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutation opens in new tab/window J. Rodon E. Rodriguez ∙ M.L. Maitland ∙ F.Y.-C. Tsai ∙ M.A. Socinsk ∙ J.D. Berlin ∙ J.S. Thomas ∙ T. Al Baghdadi∙I.-M. Wang ∙ C. Guo10 ∙ M. Golmakani9 ∙ L.N. Clark9 ∙ M. Gazdoiu9,† ∙ M. Li9 ∙ A.W. Tolcher

• Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study opens in new tab/window S. Joris ∙ H. Denys ∙ J. Collignon ∙ M. Rasschaert4 ∙ D. T’Kint de Roodenbeke ∙ F.P. Duhoux∙ J.-L. Canon ∙ S. Tejpar ∙ J. Mebis

Immuno-Oncology and Technology

• Distinct spatial landscapes in clear-cell renal cell carcinoma as revealed by whole transcriptome analysis opens in new tab/window J.I. López ∙ M.F. Hogan ∙ B. Sutton ∙ S.E. Church ∙ J.C. Angulo ∙ C.E. Nunes-Xavier

• Rational engineering of an improved adenosine deaminase 2 enzyme for weaponizing T-cell therapies opens in new tab/window J.R. Cox ∙ M. Jennings ∙ C. Lenahan ∙ M. Manion ∙ S. Courville ∙ J. Blazeck

• Non-viral chimeric antigen receptor (CAR) T cells going viral opens in new tab/window H. Balke-Want ∙ V. Keerth ∙ A. Cadinanos-Garai ∙ C. Fowler ∙ N. Gkitsas ∙ A.K. Brown ∙ R. Tunuguntla ∙ M. Abou-el-Enein ∙ S.A. Feldman

ESMO Gastrointestinal Oncology

• Consistency of a clinical decision support system with molecular tumour board recommendations for tumour sequencing opens in new tab/window M. Kordes,† ∙ L. Malgerud,†,‡ ∙ J.-E. Frödin ∙ J. Yachnin ∙ C. Fernandez Moro ∙ S. Ghazi ∙ R. Pozzi Mucelli ∙ N. Kartalis ∙ P. Ghorbani ∙ M. Del Chiaro∙ V. Wirta ∙ M. Björnstedt ∙ M.G. Liljefors ∙ J.-M. Löhr

• Current practices and challenges in implementing precision medicine for upper gastrointestinal cancers in European opens in new tab/window M. Alsina ∙ A.E. Huerta ∙ F. Lordick ∙ S. Verschueren ∙ M. Moehler ∙ E. Fontana ∙ E. Smyth ∙ F. Sclafani∙ A.D. Wagner ∙ L. Rimassa∙ A. Lamarca ∙ C. Neuzillet ∙ R. Obermannová

• Targeted therapies in biliary tract cancer—when precision becomes imprecise opens in new tab/window C.J. O’Rourke ∙ J.V. Schou ∙ J.B. Andersen ∙ D. Høgdall

ESMO Real World Data and Digital Oncology

• Toward optimizing patient selection for EGFR antibody therapies in metastatic colorectal cancer: outcomes and resistance features in real-world data opens in new tab/window M.J. Emmett ∙ J.C.F. Quintanilha,† ∙ R.P. Graf ∙ G. L ∙ H. Tukachinsky∙ A.B. Schrock ∙ S. Morley ∙ V.A. Fisher ∙ G.R. Oxnard ∙ C.H. Lieu∙ P.A. Myer ∙ S.J. Klempner

• Safety and efficacy of encorafenib–cetuximab combination in BRAFV600E-mutated metastatic colorectal cancer: real-world evidence from the CONFIDENCE Spanish multicenter study opens in new tab/window A. Fernández-Montes ∙ J. Ros ∙ P. García-Alfonso∙ B. Graña∙ E. Brozos-Vázquez ∙ M. Melián ∙ A.M Jiménez-Gordo ∙ E. Martínez de Castro ∙ I. Busquier ∙ A. Ferrández Arias ∙ C. Grávalos ∙ M. Covela ∙ A. Ruíz-Casado ∙ E. González-Flores ∙ M.J. Safont ∙ J.M. Cano ∙ C. Alonso-López ∙ M. J. Gómez-Reina ∙ O. Donnay ∙ J.L. Manzano-Mozo ∙ P. Sampedro Domarco ∙ E. Falcó ∙ N. Rodríguez ∙ C. García-Benito ∙ E. Arandaon behalf of the Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD

ESMO affiliated journals

• Hematological and biochemical markers influencing breast cancer risk and mortality: Prospective cohort study in the UK Biobank by multi-state models opens in new tab/window Yanyu Zhanga ∙ Xiaoxi Huangb ∙ Xingxing Yu∙ Wei He ∙ Kamila Czenee ∙ Haomin Yang

• Prevention, diagnosis and clinical management of hereditary breast cancer beyond BRCA1/2 genes opens in new tab/window A. Calabrese ∙ C. von Arx ∙ A.A. Tafuti ∙ M. Pensabene ∙ M. De Laurentii

• Early-Onset colorectal Cancer: From the laboratory to the clinic opens in new tab/window Annalice Gandinia, ∙ Julien Taiebb ∙ Hélène Blons ∙ Jeanne Netter ∙ Pierre Laurent-Puig ∙ Claire Gallois

• A biomarker exploration in small-cell lung cancer for brain metastases risk and prophylactic cranial irradiation therapy efficacy opens in new tab/window Li Lia ∙ Ning Liua ∙ Tao Zhoua ∙ Xueting Qina ∙ Xiaoyu Songa ∙ Song Wangb ∙ Jiaohui Pangb ∙ Qiuxiang Oub ∙ Yong Wanga ∙ Dexian Zhangc ∙ Jiaran Lia ∙ Fuhao Xua ∙ Shuming Shia ∙ Jinming Yua ∙ Shuanghu Yuana'

• Real-world outcomes of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC)treated with osimertinib (osi) vs. Afatinib or erlotinib opens in new tab/window Adam Barsouk ∙ Omar Elghawya ∙ Alec Heidlaufb ∙ Connie Yub ∙ Lucy Wangb ∙ David Yangb ∙ Martin Kurianb ∙ Keshav Goelb ∙ Lynn Rushkinb ∙ Anna Anran Huangb ∙ Lauren Reed-Guya ∙ Benjamin Bleiberga ∙ Lova Suna ∙ Aditi Singha ∙ Roger B. Cohena ∙ Charu Aggarwala ∙ Melina Marmarelisa ∙ Corey Langer

• T Cell Exhaustion Markers in Multiple Myeloma Patients are Lower After Physical Activity Intervention opens in new tab/window Janine M. Joseph ∙ Michaela Hillengass∙ Rikki Cannioto ∙ Joseph D. Tario∙ Paul K. Wallace∙ Kristopher Attwood∙ Adrienne Groman∙ Hillary Jacobson∙ Bryan Wittmeyer∙ Hemn Mohammadpour ∙ Scott I. Abrams ∙ Kirsten B. Moysich ∙ Jens Hillengass

• Clinical Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With Talquetamab opens in new tab/window Ajai Chari ∙ Amrita Krishnan ∙ Leo Rasche ∙ Jing Christine Ye∙ Alfred Garfall ∙ Rakesh Popat ∙ Brea Lipe ∙ Xiang Qin ∙ Michela Campagna ∙ Tara Masterson ∙ Chalmer Tomlinson ∙ Brandi Hilder ∙ Jaszianne Tolbert ∙ Thomas Renaud ∙ M. Damiette Smit ∙ Kathleen Gray ∙ Colleen Kane ∙ Christoph Heuck ∙ Niels W.C.J. van de Donk

ESMO's Journal Portfolio

While diverse in nature and in content, these journals offer ESMO members and the oncology community a highly visible platform to publish important scientific studies, and a highly credible source for educational updates. Elsevier is the proud publisher of Annals of Oncology, Immuno-Oncology and Technology (IOTECH), ESMO Open, ESMO Gastrointestinal Oncology, ESMO Real World Data and Digital Oncology, and ESMO Affiliated Journals The Breast, Lung Cancer, Cancer Treatment Reviews and Clinical Lymphoma Myeloma and Leukemia.